Back

Effects of beta-blocker treatment on circulating biomarkers of fibrosis in patients with myocardial infarction without heart failure: A substudy of the BETAMI-DANBLOCK trial

31 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: From infarction to recovery: SGLT2 and rehabilitation in heart failure Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Ida Gjervold Lunde

Oslo University Hospital Ulleval, Oslo (Norway)

6 More presentations in this session

Presentation thumbnail
Dapagliflozin attenuates post-infarction inflammation and remodeling via promoting metabolic reprogramming–driven cardiac lymphangiogenesis
Doctor Z. Zhang (CN)
Abstract
Presentation thumbnail
Heart failure therapy optimization in myocardial infarction patients with systolic dysfunction during Phase 2 and 3 Cardiac Rehabilitation
Doctor S. Cardona Tercero (Valencia, ES)
Abstract
Presentation thumbnail
Does symptom profile modify revascularization benefit in ischemic LV dysfunction? A win ratio analysis pooling STICHES and REVIVED-BCIS2
Doctor G. Tong (New Haven, US)
Abstract
Presentation thumbnail
Differences in survival outcomes and LVEF of self-expanding versus balloon expandable valves after TAVI in patients with severe cardiac dysfunction
Doctor A. Matta (Toulouse, FR)
Abstract
Presentation thumbnail
Reversal of residual left ventricular remodeling in corrected primary valvular regurgitation: is it different from dilated cardiomyopathy
Mr R. Zhang (Chengdu, CN)
Abstract

Access the full session

Session thumbnail
From infarction to recovery: SGLT2 and rehabilitation in heart failure

The Event

Event poster

ESC Congress 2026

31 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Beta-blocker therapy and angina pectoris after myocardial infarction: a BETAMI-DANBLOCK substudy
23 April 2026
thumbnail
Congress Presentation
Association between global longitudinal strain and myocardial fibrosis biomarkers in patients with end-stage chronic kidney disease
26 August 2022
thumbnail
Congress Presentation
A biomarker of collagen type I is associated with risk of mortality after ST-elevated myocardial infarction
21 May 2023
thumbnail
Congress Presentation
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources